Meridian Launches Innovative Air-Dryable™ qPCR Mixes Enabling Direct Detection of DNA or RNA from Urine Samples

Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of two innovative Air-Dryable™ qPCR Mixes that enable direct detection of DNA or RNA/DNA from urine samples. Meridian developed these unique master mixes specifically to overcome the adverse effect of inhibitors present in crude urine samples that can affect the sensitivity of a molecular assay.

Urine is an abundant biofluid used to diagnose urinary tract infections (UTIs) and sexually transmitted diseases (STDs), and manage bladder, ovarian, prostate, and kidney diseases. Urine-based biopsies are non-invasive and enable convenient at-home self-sampling, consequently increasing patient compliance and satisfaction. Urine contains substances (e.g., urea) that can inhibit PCR reactions. As such, expensive and time-consuming extraction steps are often needed. Meridian’s new Air-Dryable™ Direct DNA qPCR Urine and Air-Dryable™ Direct RNA/DNA qPCR Urine mixes remove the need for time-consuming RNA or DNA purification or complex component optimization. These mixes produce faster and more sensitive assays directly from urine. Setting up the assay can be as simple as adding primers and probes. Air-Dryable™ technology replaces the need for lyophilization with fast, simple, and inexpensive oven-drying procedures. Meridian’s mixes are ideal for manufacturing room-temperature stable, highly sensitive, and cost-effective molecular diagnostic assays.

Florent Chang-Pi-Hin, Ph.D., Vice President of Research & Development at Meridian Life Science, commented, “Urine can be a rich source of material for testing a wide variety of conditions as it is easily accessible and convenient for patients to provide in comparison to other liquid biopsy material such as blood. Interestingly, we have shown that the Air-Dryable™ Direct qPCR Urine mixes are sensitive enough to detect and distinguish co-infecting arboviruses such as Dengue, Zika, and Chikungunya in urine long after the disappearance of viremia in the blood. The Air-Dryable™ Direct qPCR Urine mixes are ideal for developing point-of-care assays with faster workflows and market-leading performance. Meridian’s Air-Dryable™ technology allows oven-drying on-site, saving manufacturing time and expense while allowing control of the entire workflow.”

Meridian is committed to supplying innovative solutions to the diagnostic industry to simplify and accelerate the development of superior diagnostic assays.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.